<DOC>
<DOCNO>
EP-0010234
</DOCNO>
<TEXT>
<DATE>
19800430
</DATE>
<IPC-CLASSIFICATIONS>
C07D-285/20 A61P-9/00 A61P-9/12 A61K-31/5415 C07D-285/00 A61K-31/54 
</IPC-CLASSIFICATIONS>
<TITLE>
3,3-substituted spiro-1,2,4-benzothiadiazines and pharmaceutical compositions containing the same.
</TITLE>
<APPLICANT>
merck & co incus<sep>merck & co., inc.<sep>merck &amp; co., inc.126, east lincoln avenue p.o. box 2000rahway new jersey 07065-0900us<sep>
</APPLICANT>
<INVENTOR>
cragoe jr edward jethrous<sep>woltersdorf jr otto williamus<sep>cragoe, jr., edward jethro<sep>woltersdorf, jr., otto william<sep>cragoe, jr., edward jethro2211 oak terrace drivelansdale, pennsylvania 19446us<sep>woltersdorf, jr., otto william200 dorset waychalfont, pennsylvania 18914us<sep>
</INVENTOR>
<ABSTRACT>
new 3,3-substituted spiro-1,2,4-benzothiadiazines of the  formula i, wherein x¹ is h or halo or trifluoromethyl, x² is h,  halo or -so₂nh₂, r is h or lower alkyl, r¹ is h or lower alkyl, r²  is lower alkyl or cycloakyl, r¹ and r² may be joined to form -  (ch₂)-₄ or ₅,r³ is h, lower alkyl or aryl, m is 0 or 1 and n is 0 or 5  and pharmaceutically acceptable salts thereof, are prepared  by reacting an aniline compound of the formula ii with a keton  of the formula iii, preferably in the ketal form, wherein the  substituents of ii and iii are the same as described above,  preferably in the presence of a mineral acid catalyst.  the compounds i are provided in pharmaceutical anti-­ hypertensive compositions.   
</ABSTRACT>
</TEXT>
</DOC>
